Ardelyx/ARDX

$7.06

-4.33%
-
1D1W1MYTD1YMAX

About Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Ticker

ARDX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Raab

Employees

267

Headquarters

Fremont, United States

Ardelyx Metrics

BasicAdvanced
$1.64B
Market cap
-
P/E ratio
-$0.30
EPS
0.83
Beta
-
Dividend rate
$1.64B
0.83394
$10.13
$3.16
5.58M
4.884
4.637
29.866
29.866
-12.7%
-27.1%
-49.83%
-35.55%
13.2
9.838
9.848
138.61%
37.05%
154.27%

What the Analysts think about Ardelyx

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
91.93% upside
High $16.00
Low $11.00
$7.06
Current price
$13.55
Average price target

Ardelyx Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-83.96% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$34.3M
-39.08%
Net income
$-28.8M
-536.36%
Profit margin
-83.96%
-816.38%

Ardelyx Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 26.61%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.13
-$0.08
$0.03
-$0.12
-
Expected
-$0.10
-$0.11
-$0.11
-$0.09
-$0.15
Surprise
29.35%
-30.17%
-128.07%
26.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Ardelyx stock?

Ardelyx (ARDX) has a market cap of $1.64B as of April 14, 2024.

What is the P/E ratio for Ardelyx stock?

The price to earnings (P/E) ratio for Ardelyx (ARDX) stock is 0 as of April 14, 2024.

Does Ardelyx stock pay dividends?

No, Ardelyx (ARDX) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Ardelyx dividend payment date?

Ardelyx (ARDX) stock does not pay dividends to its shareholders.

What is the beta indicator for Ardelyx?

Ardelyx (ARDX) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Ardelyx stock price target?

The target price for Ardelyx (ARDX) stock is $13.55, which is 91.93% above the current price of $7.06. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ardelyx stock

Buy or sell Ardelyx stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing